Plasma Fractionation Market Outlook:
Plasma derived immunoglobulins are being increasingly used in multiple clinical indications such as autoimmune and inflammatory diseases. The plasma fractionation market has heavily invested in therapies such as Ceruloplasmin, IgA and Plasmin. In addition, burgeoning investments in innovation and technological advancements in efficient and cost-effective procedures for fractioning proteins shall give impetus to the market.
On the back of the aforementioned trends, the global plasma fractionation market is poised to experience an uptick in the forecast period (2020-2026). Anticipated CAGR for the market is pegged at a staggering 7.1%. The COVID-19 pandemic is anticipated to generate potential growth opportunities for the plasma fractionation market. This is attributed to the efforts by key players to collaborate on convalescent plasma (CP) extraction and study its effects on COVID-19 patients.
Plasma Fractionation Market Share Analysis by Application:
The neurology segment is anticipated to enjoy the lion’s share of the plasma fractionation market. A spurt in neurological disorders is responsible for the growing scope of the neurology segment. Fact.MR projects that neurological disorders plague more than 450 million people globally. The neurology segment shall account for more than two-fifths of the plasma fractionation market, leveraging at a CAGR of 7.2%.
Trailing behind is the immunology segment, expanding 1.5x during the forecast period. Rising popularity of immunoglobulins as an important treatment option for autoimmune and inflammatory diseases is anticipated to be a key growth driver. The immunology segment is anticipated to capture almost one-third of the plasma fractionation market, reaching a value of US$ 10 Bn by the end of 2026.
To get the latest COVID-19 impact insights on the plasma fractionation market, ask an analyst here
Plasma Fractionation Market Analysis by Region:
The North American plasma fractionation market shall lay suzerainty during the forecast period. The North American region is set to capture nearly 2/5th of the plasma fractionation market, expanding at a CAGR of 6.6%. A robust healthcare sector along with continuous technological innovation shall accelerate demand for plasma fractionation in North America. Moreover, the prevalence of neurological and autoimmune diseases as well as hemophilia shall boost demand prospects for plasma fractionation.
Asia-Pacific shows a promising outlook for the growth of the plasma fractionation market. Therapeutic applicability of plasma fractionation proteins is an important growth lever for the Asia-Pacific market. Moreover, technological improvements in healthcare sectors of emerging economies are anticipated to pave way for exciting market prospects during the forecast period. Projected CAGR for the Asia-Pacific market is pegged at a staggering 8.0%. Also, prevalence of immune and bleeding disorders have prompted investments in plasma fractionation techniques.
Access our exhaustive repertoire of in-depth regional insights on the plasma fractionation market by requesting for a report sample here
Plasma Fractionation Companies: Nuanced Research Trump Card for Key Players
The plasma fractionation market consists of multiple players. These are: CSL Behring, Shire plc, Sanquin, Biotest AG, GRIFOLS, Baxter International Inc., Kedrion, Octapharma USA Inc. to name a few. Innovative product offerings and new product development are key growth strategies adopted by market players.
CSL Behring, for instance, markets the Privigen, Carimune, Snadoglobulin and Hizentra solutions. Sanquin produces four types of plasma products using various isolation techniques: coagulation factors, protease inhibitors, immunoglobulins and albumin. The company also offers contract fractionation services.
Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs. It leads in the field of plasma collection. Biotest AG presently develops plasma proteins for Primary Immune Deficiency (PID) and various hyperimmune products. Examples of the products offered are Varitect, Cytotect CP and Albiomin.
COVID-19 Market Insights:
The COVID-19 pandemic is set to offer significant growth opportunities for the plasma fractionation market. Several countries are experimenting with plasma fractionation techniques to find potential cures and diagnostic methodologies for the novel coronavirus. A potential method of curing COVID-19 positive patients is the usage of convalescent plasma (CP). The plasma is extracted from the blood of a formerly infected person and then administered to an existing patient. The patient therefore acquires passive immunization as the plasma is said to contain critical antibodies to fight the virus.
Octapharma, a leading pharmaceutical company, is putting its expertise to work to find new treatments for COVID-19. It is doing so by collaborating with leading plasma fractionation players in order to develop a potential plasma-derived hyperimmune immunoglobulin therapy. The alliance is investigating the development of one unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine. The medicine has the potential to treat patients with severe COVID-19 symptoms. The alliance includes companies such as CSL Behring, Takeda BPL, Biotest and LFB.
Likewise, Grifols has entered into a formal collaboration with the United States Biomedical Advanced Research Department Authority (BARDA), the FDA and other federal public health authorities. The company is collecting convalescent plasma to support the necessary preclinical and clinical studies to determine if the anti-SARS-CoV-2 hyperimmune immunoglobulin is effective to treat COVID-19.
Analyst’s Viewpoint:
The plasma fractionation market is poised to embark on a positive growth trajectory. Rising technological innovation and augmenting demand for plasma proteins are credited as important growth drivers. Moreover, the COVID-19 pandemic has prompted market players to invest in developing plasma-based solutions to eradicate the disease. Regionally, North America is poised to retain market hegemony while Asia-Pacific promises attractive growth opportunities.
Plasma Fractionation Market: Report Scope:
The recent study by Fact.MR on plasma fractionation incorporates a six-year forecast period, elucidating on the potential drivers, opportunities and restraints across key segments and regions. The plasma fractionation market has been segmented on the basis of product type, application and end-users. Each segment contains a detailed analysis of their market share and revenue.
A detailed regional analysis for five geographies has been embedded in the report. These regions are North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA). Each region includes the segmental analysis highlighted above. In addition, a competition landscape has also been included. This section provides details about the key market players, their revenue, and their strategies for expansion and product launches. Moreover, a SWOT analysis has been provided to provide a realistic picture for future prospects of the market players.
Plasma Fractionation Market- Scope of the Report
The recent study by Fact.MR on plasma fractionation market offers a 6-year forecast between 2020 and 2026. The study analyzes crucial trends that are currently determining the growth of the plasma fractionation market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the provision of plasma fractionation services. The study also provides dynamics that are responsible for influencing the future status of the plasma fractionation market over the forecast period.
A detailed assessment of the plasma fractionation market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the plasma fractionation market along with their product portfolio enhances the reliability of this comprehensive research study.
Plasma Fractionation Market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the plasma fractionation market across the globe.
A comprehensive estimate on the plasma fractionation market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of plasma fractionation market during the forecast period.
Plasma Fractionation Market Segmentation
Fact.MR has studied the plasma fractionation market with detailed segmentation on the basis of product, application, end-user and region.
|
Product |
Application |
End-user |
Region |
|
Immunoglobulins:
|
Neurology |
Hospitals & Clinics |
North America |
|
Coagulation Factor Concentrates:
|
Immunology |
Clinical Research Laboratories |
Europe |
|
Albumin |
Hematology |
Academic Institutions |
Asia Pacific |
|
Protease Inhibitors |
Critical Care |
|
Latin America |
|
Other Plasma Products |
Pulmonary |
|
Middle East & Africa |
|
|
Other Applications |
|
|
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Plasma Fractionation Market: Analysis on Market Size Evaluation
The plasma fractionation market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for Plasma fractionation market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent plasma fractionation market segments, along with market attractiveness evaluation has been incorporated in the report.
Plasma Fractionation Market: Inspected Assessment on Regional Segments
Key sections have been elaborated in the plasma fractionation report, which have helped deliver projection on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the plasma fractionation market during the forecast period.
Country-specific valuation on demand for plasma fractionation has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value for emerging countries has also been included in the report.
Plasma Fractionation Market: In-Depth Analysis on Competitive Landscape
The report sheds light on the leading manufacturers of plasma fractionation products along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of plasma fractionation products, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, such as product portfolio, key strategies along with an all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the plasma fractionation market. Prominent manufacturers with established market presence in global Plasma fractionation market are GRIFOLS, Sanquin, CSL Behring Limited, Shire Plc., Biotest AG, Baxter International, etc.
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Our Clients
Plasma Fractionation Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026